Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

US pharma major Merck & Co has secured a key endorsement for its newly approved respiratory syncytial virus (RSV) prevention ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Centers for Disease Control and ...

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy preterm and full-term infants, putting MSD in a position to potentially file ...